| Literature DB >> 28794359 |
Yu Nishida1, Shuhei Hosomi1, Hirokazu Yamagami1, Tomomi Yukawa1, Yasuaki Nagami1, Fumio Tanaka1, Noriko Kamata1, Tetsuya Tanigawa1, Masatsugu Shiba1, Toshio Watanabe1, Kazunari Tominaga1, Yasuhiro Fujiwara1, Tetsuo Arakawa1.
Abstract
Objective Balloon-assisted endoscopy enables access to and treatment of strictures in the small intestine using endoscopic balloon dilation (EBD); however, the long-term outcomes of EBD have not been sufficiently evaluated. This study evaluated the long-term outcomes of EBD in Crohn's disease to identify the risk factors associated with the need for subsequent surgical intervention. Methods We retrospectively analyzed patients with Crohn's disease who had undergone EBD with double-balloon endoscopy (DBE) for small intestinal strictures at a single center between 2006 and 2015. The long-term outcomes were assessed based on the cumulative surgery-free rate following initial EBD. Results Seventy-two EBD with DBE sessions and 112 procedures were performed for 37 patients during this period. Eighteen patients (48.6%) required surgery during follow-up. Significant factors associated with the need for surgery in a multivariate analysis were multiple strictures (adjusted hazard ratio, 14.94; 95% confidence interval, 1.91-117.12; p=0.010). One patient (6.7%) required surgery among 15 who had single strictures compared to 17 (77.3%) among 22 patients with multiple strictures. Conclusion In a multivariate analysis, the presence of multiple strictures was a significant risk factor associated with the need for surgery; therefore, a single stricture might be a good indication for EBD using DBE for small intestinal strictures in Crohn's disease patients.Entities:
Keywords: Crohn's disease; double balloon endoscopy; endoscopic balloon dilation; inflammatory bowel disease; small intestinal stricture
Mesh:
Year: 2017 PMID: 28794359 PMCID: PMC5635294 DOI: 10.2169/internalmedicine.8224-16
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Baseline Characteristics at Initial Endoscopic Balloon Dilation.
| Number of patients | 37 |
| Gender: male/female | 31/6 |
| Age at diagnosis, median (interquartile range) | 24.7 (20.5–28.4) years |
| Age at initial dilation, median (interquartile range) | 35.0 (31.8–37.9) years |
| Disease duration at initial dilation, median (interquartile range) | 10.0 (5.5–14.0) years |
| Smoker, n (%) | 7 (18.9%) |
| Disease location at initial dilation, n (%) | |
| Ileal (L1) | 21 (56.8%) |
| Colonic (L2) | 0 (0%) |
| Ileocolonic (L3) | 16 (43.2%) |
| Behaviour at initial dilation, n (%) | |
| Non-stricturing, non-penetrating (B1) | 0 (0%) |
| Stricturing (B2) | 28 (75.7%) |
| Penetrating (B3) | 9 (24.3%) |
| Presence of jejunal stricture(s) | 5 (13.5%) |
| Presence of peri-anal disease, n (%) | 13 (35.1%) |
| Pre-stenotic dilatation, n (%) | 31 (83.8%) |
| Type of stricture, n (%) | |
| 31 (83.8%) | |
| anastomosis | 6 (16.2%) |
| Number of strictures, n (%) | |
| Single | 15 (40.5%) |
| Multiple (two or more) | 22 (59.5%) |
| Length of strictures, n(%) | |
| Short | 15 (40.5%) |
| Long | 22 (59.5%) |
| Concomitant therapies at initial dilation, n (%) | |
| Steroids | 2 (5.4%) |
| Immunomodulators (azathioprine or 6-mercaptopurine) | 11 (29.7%) |
| Biologics (infliximab or adalimumab) | 20 (54.1%) |
| Follow-up time, median (interquartile range) | 27.1 (1.6–59.3) months |
Figure 1.The cumulative surgery-free rates among all subjects were 63.1%, 59.9%, and 56.2% at 1, 2, and 3 years, respectively (the Kaplan-Meier method).
Figure 2.The cumulative surgery-free rates of endoscopic balloon dilation according to the number of strictures (the Kaplan-Meier method).
Cox Regression Analysis of Risk for Subsequent Surgery (Surgical Bowel Resection or Strictureplasty) during Follow-up after Initial Dilation.
| No. of events | Rate | Unadjusted HR (95%CI) | p value | Adjusted HR(95%CI) | p value | |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male, n=31 | 14 | 0.45 | ||||
| Female, n=6 | 4 | 0.67 | 1.49 (0.49–4.57) | 0.483 | ||
| Age at diagnoisis | ||||||
| <25 years, n=19 | 10 | 0.53 | ||||
| 25≤ years, n=18 | 8 | 0.44 | 1.04 (0.41–2.65) | 0.936 | ||
| Age at initial dilation | ||||||
| <40 years, n=31 | 16 | 0.52 | ||||
| 40≤ years, n=6 | 2 | 0.33 | 0.71 (0.16–3.14) | 0.638 | ||
| Smoking habit at dilation | ||||||
| Non-smoker, n=30 | 15 | 0.50 | ||||
| Smoker, n=7 | 3 | 0.43 | 0.87 (0.25–3.03) | 0.828 | ||
| Disease duration at initial dilation | ||||||
| <10.0 years, n=18 | 7 | 0.39 | ||||
| 10≤ years, n=19 | 11 | 0.58 | 1.88 (0.72–4.90) | 0.199 | ||
| Disease location at initial dilation | ||||||
| Ileal (L1), n=21 | 9 | 0.43 | ||||
| Ileocolonic (L3), n=16 | 9 | 0.56 | 1.66 (0.66–4.21) | 0.284 | ||
| Behaviour at initial dilation | ||||||
| Stricturing (B2), n=28 | 14 | 0.50 | ||||
| Penetrating (B3), n=9 | 4 | 0.44 | 1.37 (0.44–4.30) | 0.593 | ||
| Presence of jejunal stricture(s) | ||||||
| No, n=32 | 13 | 0.41 | ||||
| Yes, n=5 | 5 | 1.00 | 3.69 (1.27–10.68) | 0.016 | 1.37 (0.42–4.48) | 0.606 |
| Presence of peri-anal disease | ||||||
| No, n=24 | 11 | 0.46 | ||||
| Yes, n=13 | 7 | 0.54 | 1.47 (0.56–3.86) | 0.439 | ||
| Pre-stenotic dilatation | ||||||
| No, n=6 | 1 | 0.17 | ||||
| Yes, n=31 | 17 | 0.55 | 4.75 (0.63–35.73) | 0.131 | 3.68 (0.47–28.93) | 0.215 |
| Type of stricture(s) | ||||||
| 17 | 0.55 | |||||
| Anastomosis, n=6 | 1 | 0.17 | 0.33 (0.04–2.49) | 0.281 | ||
| Number of stricture(s) | ||||||
| Single, n=15 | 1 | 0.07 | ||||
| Multiple (two or more), n=22 | 17 | 0.77 | 19.79 (2.61–150.06) | 0.004 | 14.94 (1.91–117.12) | 0.010 |
| Length of stricture(s) | ||||||
| Short, n=15 | 7 | 0.46 | ||||
| Long, n=22 | 11 | 0.50 | 1.76 (0.67–4.63) | 0.250 | ||
| Steroid treatment at initial dilation | ||||||
| No, n=35 | 17 | 0.49 | ||||
| Yes, n=2 | 1 | 0.50 | 0.93 (0.12–7.34) | 0.944 | ||
| Immunmodulators (azathioprine or 6-mercaptopurine) at initial dilation | ||||||
| No, n=26 | 12 | 0.46 | ||||
| Yes, n=11 | 6 | 0.55 | 1.14 (0.43–3.04) | 0.798 | ||
| Biologics (infliximab or adalimumab) at initial dilation | ||||||
| No, n=17 | 11 | 0.65 | ||||
| Yes, n=20 | 7 | 0.35 | 0.46 (0.18–1.19) | 0.108 | 0.59 (0.19–1.77) | 0.342 |
HR: hazard ratio, CI: confidence interval
Figure 3.The cumulative surgery-free rates of endoscopic balloon dilation at 3 years were 88.9% and 33.3% with single and multiple (two or more) strictures, respectively (the Kaplan-Meier method).
Clinical Background of Patients with Multiple Strictures with Operation and without Operation.
| With operation (n=17) | Without operation (n=5) | p value | |
|---|---|---|---|
| Gender (M/F) | 13/4 | 5/0 | 0.535 |
| Age, median (interquartile range) | 34.2 (30.8–37.0) years | 37.4 (32.4–37.7) years | 0.649 |
| Disease duration, median (interquartile range) | 7.4 (6.7–9.3) years | 10.1 (5.0–13.1) years | 0.820 |
| Smoker (yes/no) | 3/14 | 1/4 | 1 |
| Location at initial dilation (Ileal (L1)/Ileocolonic (L3)) | 8/9 | 4/1 | 0.323 |
| Behaviour at initial dilation (Stricturing (B2)/Penetrating (B3)) | 13/4 | 4/1 | 1 |
| Pre-stenotic dilatation (yes/no) | 16/1 | 4/1 | 0.411 |
| Type of stricture ( | 16/1 | 3/2 | 0.117 |
| Number of strictures, mean (range) | 2.7 (2–5) | 2.2 (2–3) | 0.266 |
| Length of strictures, (short/long) | 7/10 | 0/5 | 0.135 |
| Concomitant therapies at initial dilation | |||
| Steroids (yes/no) | 1/16 | 0/5 | 1 |
| Immunomodulators (azathioprine or 6-mercaptopurine) (yes/no) | 5/12 | 2/3 | 1 |
| Biologics (infliximab or adalimumab) (yes/no) | 6/11 | 3/2 | 0.609 |